2021 is on track to beat last year’s monster haul, but the IPO window could finally be closing.
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Deciphera, Allakos and Uniqure are all set for important data disclosures.
The fourth quarter will see key immunotherapy data from Astrazeneca and Merck, while full details on Glaxo's anaemia pill, daprodustat, are expected.
Rilzabrutinib flunks a pivotal trial in pemphigus, but all eyes are on tolebrutinib in multiple sclerosis.
The “left field but logical” buy sees Sanofi gaining a graft-versus-host disease therapy to add to its transplant offering.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.